[Treatment of recurrent vulvovaginal candidosis with mycosyst (fluconazole)]

Related Experiment Video

Updated: Aug 16, 2026

Protocols for Vaginal Inoculation and Sample Collection in the Experimental Mouse Model of Candida vaginitis
07:57

Protocols for Vaginal Inoculation and Sample Collection in the Experimental Mouse Model of Candida vaginitis

Published on: December 8, 2011

B Pekhlivanov, I Amaliev, Kh Ivancheva

    Akusherstvo I Ginekologiia
    |July 21, 2005
    PubMed

    Insights

    This study shows sequential oral fluconazole therapy effectively treated recurrent vulvovaginal candidosis, with most patients remaining asymptomatic. However, Candida albicans was still detected in some patients three months post-treatment.

    Area of Science:

    • Mycology
    • Infectious Diseases
    • Pharmacology

    Background:

    • Recurrent vulvovaginal candidosis (RVVC) presents a significant clinical challenge.
    • Candida albicans is the predominant pathogen, but other species like Candida glabrata can also cause infections.

    Purpose of the Study:

    • To evaluate the efficacy of a sequential oral fluconazole regimen for treating RVVC.
    • To assess clinical outcomes and mycological recurrence rates after treatment.

    Main Methods:

    • Fifteen women with RVVC received three sequential oral 150-mg doses of fluconazole, spaced 72 hours apart.
    • Clinical assessments and vaginal discharge cultures were performed at baseline, 14 days, and 3 months post-treatment.

    Main Results:

    • All 15 women achieved clinical resolution of RVVC symptoms by day 14.
    • At the 3-month follow-up, 11 women were asymptomatic, but Candida albicans was isolated from vaginal discharge in three (23.1%) of them.
    • The study identified 14 cases of Candida albicans and one of Candida glabrata.

    Conclusions:

    • Sequential oral fluconazole therapy demonstrates high initial efficacy for RVVC.
    • Long-term mycological surveillance is crucial due to potential for asymptomatic candidal carriage post-treatment.
    • The study highlights the advantages of sequential fluconazole dosing for managing RVVC.

    More Related Videos

    Curcuminoid-Mediated Antimicrobial Photodynamic Therapy on a Murine Model of Oral Candidiasis06:39

    Curcuminoid-Mediated Antimicrobial Photodynamic Therapy on a Murine Model of Oral Candidiasis

    Published on: October 27, 2023

    Induction of Petite Colonies in Candida glabrate via Rose Bengal-Mediated Photodynamic Therapy09:06

    Induction of Petite Colonies in Candida glabrate via Rose Bengal-Mediated Photodynamic Therapy

    Published on: March 29, 2024

    Related Concept Videos

    Candidiasis01:20

    Candidiasis

    Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
    Cryptococcal Meningitis01:27

    Cryptococcal Meningitis

    Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
    Antifungal Agents01:15

    Antifungal Agents

    Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
    Trichomoniasis01:18

    Trichomoniasis

    Trichomonas vaginalis is a flagellated protozoan parasite and the causative agent of trichomoniasis, one of the most prevalent non-viral sexually transmitted infections in the United States. This extracellular parasite primarily colonizes the lower genitourinary tract in women—particularly the vagina—and in men, the urethra and prostate. Its structural and functional adaptations enable its survival, motility, and pathogenicity within the host environment.Structural Features and Host EntryT.
    Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

    Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

    In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
    In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
    Cytomegalovirus Disease01:27

    Cytomegalovirus Disease

    Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...